Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict

Annals of the New York Academy of Sciences

Volumn 910, Issue , 2000, Pages 178-195

  O'Connell, Joe ^a,b   Bennett, Michael W ^a   Nally, Kenneth ^a   Houston, Aileen ^a   O'Sullivan, Gerald C ^a   Shanahan, Fergus ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b University College Cork and INFANT Centre   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOHEXIMIDE; DOXORUBICIN; FAS ANTIGEN; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 1BETA CONVERTING ENZYME; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; CANCER CELL CULTURE; CHEMOSENSITIVITY; COLON CANCER; CONFERENCE PAPER; ESOPHAGUS CANCER; GENE MUTATION; LIVER METASTASIS; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE;

EID: 0033913693     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2000.tb06708.x     Document Type: Conference Paper

References (85)

1. 1. NAGATA, S. 1997. Apoptosis by death factor. Cell 88: 355-365.
2. 2. TRAUTH, B.C., C. KLAS, A.M.J. PETERS, S. MATZUKU, P. MOLLER, W. FALK, K.-M. DEBATIN & P.H. KRAMMER. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245: 301-305.
3. 3. CONEY, L.R., P.T. DANIEL, D. SANBORN, J. DHEIN, K.M. DEBATIN, P.H. KRAMMER & V.R. ZURAWSKI, JR. 1994. Apoptotic cell death induced by a mouse-human anti-APO-1 chimeric antibody leads to tumor regression. Int. J. Cancer 58: 562-567.
4. 4. LUCKING-FAMIRA, K.M., P.T. DANIEL, P. MOLLER, P.H. KRAMMER & K.M. DEBATIN. 1994. APO-1 (CD95) mediated apoptosis in human T-ALL engrafted in SCID mice. Leukemia 8: 1825-1833.
5. 5. O'CONNELL, J., G.C. O'SULLIVAN, J.K. COLLINS & F. SHANAHAN. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184: 1075-1082.
6. 6. SHIMA, Y., N. NISHIMOTO, A. OGATA, Y. FUJII, K. YOSHIZAKI & T. KISHIMOTO. 1995. Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis. Blood 85: 757-764.
7. 7. OWEN-SCHAUB, L.B., R. RADINSKY, E. KRUZEL, K. BERRY & S. YONEHARA. 1994. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and Bcl-2 are not predictive of biological responsiveness. Cancer Res. 54: 1580-1586.
8. 8. O'CONNELL, J., M.W. BENNETT, G.C. O'SULLIVAN, J.K. COLLINS & F. SHANAHAN. 1997. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol. Med. 3: 294-300.
9. 9. STRATER, J., I. WELLISCH, S. RIEDL, H. WALCZAK, K. KORTEZ, A. TANDARA, P.H. KRAMMER & P. MOLLER. 1997. CD95 (APO-1/Fas)-mediated apoptosis in colon epithelial cells: a possible role in ulcerative colitis. Gastroenterology 113: 160-167.
10. 10. RUEMMELE, F.M., P. RUSSO, J. BEAULIEU, S. DIONNE, E. LEVY, M.J. LENTZE & E.G. SEIDMAN. 1999. Susceptibility to Fas-induced apoptosis in human nontumoral enterocytes: role of costimulatory factors. J. Cell. Physiol. 181: 45-54.
11. 11. O'CONNELL, J., M.W. BENNETT, G.C. O'SULLIVAN, D. ROCHE, J. KELLY, J.K. COLLINS & F. SHANAHAN. 1998. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 186: 240-246.
12. 12. MOLLER, P., K. KORETZ, F. LEITHAUSER, S. BRUDERLEIN, C. HENNE, A. QUENTMEIER & P.M. KRAMMER. 1994. Expression of APO-1 (CD95), a member of the NGF/TNF receptor superfamily, in normal and neoplastic colon epithelium. Int. J. Cancer 57: 371-377.
13. 13. STRAND, S., W.J. HOFMANN, H. HUG, M. MULLER, G. OTTO, D. STRAND, S.M. MARIANI, W. STREMMEL, P.H. KRAMMER & P.R. GALLE. 1996. Lymphocyte apoptosis induced by CD95 (Apo-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med. 2: 1361-1366.
14. 14. KNIPPING, E., K.-M. DEBATIN, K. STRICKER, B. HEILIG, A. EDAR & P.H. KRAMMER. 1995. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 85: 1562-1569.
15. 15. OWEN-SCHAUB, L.B., L.S. ANGELO, R. RADINSKY, C.F. WARE, T.G. GESNER & D.P. BARTOS. 1995. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett. 94: 1-8.
16. 16. TACHIBANA, O., H. NAKAZAWA, J. LAMPE, K. WATANABE, P. KLEIHUES & H. OHGAKI. 1995. Expression of Fas/APO-1 during the progression of astrocytomas. Cancer Res. 55: 5528-5530.
17. 17. NATOLI, G., A. IANNI, A. COSTANZO, G. DE PETRILLO, I. ILARI, P. CHIRILLO, C. BALSANO & M. LEVRERO. 1995. Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 11: 1157-1164.
18. 18. CASCINO, I., G. PAPOFF, R. DE MARIA, R. TESTI & G. RUBERTI. 1996. Fas/APO-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis. J. Immunol. 156: 13-17.
19. 19. HUGHES, S.J., Y. NAMBU, O.S. SOLDES, D. HAMSTRA, A. REHEMTULLA, M.D. IANNETTONI, M.B. ORRINGER & D.G. BEER. 1997. Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. Cancer Res. 57: 5571-5578.
20. 20. MEDEMA, J.P., C. SCAFFIDI, F.C. KISCHKEL, A. SHEVCHENKO, M. MANN, P.H. KRAMMER & M.E. PETER. 1997. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 16: 2794-2804.
21. 21. CHINNAIYAN, A.M., K. O'ROURKE, M. TEWARI & V.M. DIXIT. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512.
22. 22. MUZIO, M., A.M. CHINNAIYAN, F.C. KISCHKEL, K. O'ROURKE, A. SHEVCHENKO, J. NI, C. SCAFFIDI, J.D. BRETZ, M. ZHANG, R. GENTZ, M. MANN, P.H. KRAMMER, M.E. PETER & V.M. DIXIT. 1996. FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell 85: 817-827.
23. 23. MARTIN, S.J. & D.R. GREEN. 1995. Protease activation during apoptosis: death by a thousand cuts? Cell 82: 349-352.
24. 24. MANDRUZZATO, S., F. BRASSEUR, G. ANDRY, T. BOON & P. VAN DER BRUGGEN. 1997. A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J. Exp. Med. 186: 785-793.
25. 25. IRMLER, M., M. THOME, M. HAHNE, P. SCHNEIDER, K. HOFMANN, V. STEINER, J.L. BODMER, M. SCHROTER, K. BURNS, C. MATTMANN, D. RIMOLDI, L.E. FRENCH & J. TSCHOPP. 1997. Inhibition of death receptor signals by cellular FLIP. Nature 388: 190-195.
26. 26. WALLACH, D. 1997. Placing death under control. Nature 388: 123-126.
27. 27. MEDEMA, J.P., J. DE JONG, T. VAN HALL, C.J.M. MELIEF & R. OFFRINGA. 1999. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190: 1033-1038.
28. 28. SATO, T., S. IRIE, S. KITADA & J.C. REED. 1995. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 268: 411-415.
29. 29. ARAI, M., M. KANNAGI, M. MATSUOKA, T. SATO, N. YAMAMOTO & M. FUJII. 1998. Expression of FAP-1 (Fas-associated phosphatase) and resistance to Fas-mediated apoptosis in T cell lines derived from human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis patients. AIDS Res. Hum. Retroviruses 14: 261-267.
30. 30. OKURA, T., L. GONG, T. KAMITANI, T. WADA, I. OKURA, C.-F. WEI, H.-M. CHANG & E.T.H. YEH. 1996. Protection against Fas/APO-1 and tumor necrosis factor-mediated cell death by a novel protein, sentrin. J. Immunol. 157: 4277-4281.
31. 31. YANAGISAWA, J., M. TAKAHASHI, H. KANKI, H. YANO-YANAGISAWA, T. TAZUNOKI, E. SAWA, T. NISHITOBA, M. KAMISHOHARA, E. KOBAYASHI, S. KATAOKA & T. SATO. 1997. The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J. Biol. Chem. 272: 8539-8545.
32. 32. O'CONNELL, J., M.W. BENNETT, G.C. O'SULLIVAN, J. K. COLLINS & F. SHANAHAN. 1997. Molecular mechanisms of Fas resistance and sensitivity of colonie epithelia. Gastroenterology 112: A1053.
33. 33. KEANE, M.M., S.A. ETTENBERG, G.A. LOWREY, E.K. RUSSELL & S. LIPKOWITZ. 1996. Fas expression and function in normal and malignant breast cell lines. Cancer Res. 56: 4791-4798.
34. 34. OSSINA, N.K., A. CANNAS, V.C. POWERS, P.A. FITZPATRICK, J.D. KNIGHT, J.R. GILBERT, E.M. SHEKHTMAN, L.D. TOMEI, S.R. UMANSKY & M.C. KIEFER. 1997. Interferon-γ modulates a p53-independent apoptotic pathway and apoptosis-related gene expression. J. Biol. Chem. 272: 16351-16357.
35. 35. JARRY, A., G. VALLETTE, E. CASSAGNAU, A. MOREAU, C. BOU-HANNA, P. LEMARRE, E. LETESSIER, J.-C. LE NEEL, J.-P. GALMICHE & C.L. LABOISSE. 1999. Interleukin 1 and interleukin 1β converting enzyme (caspase-1) expression in the human colonie epithelial barrier. Caspase-I downregulation in colon cancer. Gut 45: 246-251.
36. 36. TAMURA, T., S. UEDA, M. YOSHIDA, M. MATSUZAKI, H. MOHRI & T. OKUBO. 1996. Interferon-γ induces ICE gene expression and enhances cellular susceptibility to apoptosis in the U937 leukemia cell line. Biochem. Biophys. Res. Commun. 229: 21-26.
37. 37. KROEMER, G. 1997. The proto-oncogene Bcl-2 and its role in regulating apoptosis. The mechanism of action of Bcl-2 provides clues for therapeutic interventions. Nature Med. 3: 614-620.
38. 38. ITOH, N., Y. TSUJIMOTO & S. NAGATA. 1993. Effect of Bcl-2 on Fas antigen-mediated cell death. J. Immunol. 151: 621-627.
39. 39. HUANG, D.C.S., S. CORY & A. STRASSER. 1997. Bcl-2, Bcl-xL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene 14: 405-414.
40. 40. WELLER, M., U. MALIPIERO, A. AGUZZI, J. C. REED & A. FONTANA. 1995. Protooncogene Bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95: 2633-2643.
41. 41. JAATTELA, M., M. BENEDICT, M. TEWARI, J.A. SHAYMAN & V.M. DIXIT. 1995. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene 10: 2297-2305.
42. 42. WATSON, A.J., A.J. MERRITT, L.S. JONES, J.N. ASKEW, E. ANDERSON, A. BECCIOLINI, M. BALZI, C.S. POTTEN & J.A. HICKMAN. 1996. Evidence of reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br. J. Cancer 73: 889-895.
43. 43. BARGOU, R.C., P.T. DANIEL, M.Y. MAPARA, K. BOMMERT, C. WAGENER, B. KALLINICH, H.D. ROYER & B. DORKEN. 1995. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int. J. Cancer 60: 854-859.
44. 44. BARGOU, R.C., C. WAGENER, K. BOMMERT, M.Y. MAPARA, P.T. DANIEL, W. ARNOLD, M. DIETEL, H. GUSKI, A. FELLER, H.D. ROYER & B. DORKEN. 1996. Overexpression of the death-promoting gene bax-alpha which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J. Clin. Invest. 97: 2651-2659.
45. 45. KRAJEWSKA, M., S.F. MOSS, S. KRAJEWSKI, K. SONG, P.R. HOLT & J.C. REED. 1996. Elevated expression of Bcl-x and reduced Bak in primary colorectal adenocarcinomas. Cancer Res. 56: 2422-2427.
46. 46. RAMPINO, N., H. YAMAMOTO, Y. IONOV, Y. LI, H. SAWAI, J.C. REED & M. PERUCHO. 1997. Somatic frameshift mutations in the Bax gene in colon cancers of the microsatellite mutator phenotype. Science 275: 967-969.
47. 47. VON REYHER, U., J. STRATER, W. KITTSTEIN, M. GSCHWENDT, P. H. KRAMMER & P. MOLLER. 1998. Colon carcinoma cells use different mechanisms to escape CD95-mediated apoptosis. Cancer Res. 58: 526-534.
48. 48. SU, X., T. ZHOU, Z. WANG, P. YANG, R.S. JOPE & J.D. MOUNTZ. 1995. Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cells blocks Fas-mediated apoptosis. Immunity 2: 353-362.
49. 49. TAMURA, T., N. AOYAMA, H. SAYA, H. HAGA, S. FUTAMI, M. MIYAMOTO, T. KOH, T. ARIYASU, M. TACHI, M. KASUGA et al. 1995. Induction of Fas-mediated apoptosis in p53-transfected human colon carcinoma cells. Oncogene 11: 1939-1946.
50. 50. MCGAHON, A.J., W.K. NISHIOKA, S.J. MARTIN, A. MAHBOUBI, T.G. COTTER & D.R. GREEN. 1995. Regulation of the Fas apoptotic cell death pathway by Abl. J. Biol. Chem. 270: 22625-22631.
51. 51. MULLER, M., S. STRAND, H. HUG, E.M. HEINEMANN, H. WALCZAK, W.J. HOFMANN, W. STREMMEL, P.H. KRAMMER & P.R. GALLE. 1997. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99: 403-413.
52. 52. GULBINS, E., R. BISSONNETTE, A. MAHBOUBI, S. MARTIN, W. NISHIOKA, T. BRUNNER, G. BAIER, G. BAIER-BITTERLICH, C. BYRD, F. LANG et al. 1995. Fas-induced apoptosis is mediated via a ceramide-initiated RAS signaling pathway. Immunity 2: 341-351.
53. 53. HUEBER, A.-O., M. ZORNIG, D. LYON, T. SUDA, S. NAGATA & G. I. EVAN. 1997. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science 278: 1305-1309.
54. 54. SPENCER, C.A. & M. GROUDINE. 1991. Control of c-Myc regulation in normal and neoplastic cells. Adv. Cancer Res. 56: 1-48.
55. 55. GREEN, D. 1997. A Myc-induced apoptosis pathway surfaces. Science 278: 1246-1247.
56. 56. ZORNIG, M., A. GRZESCHICZEK, M.B. KOWALSKI, K.U. HARTMANN & T. MOROY. 1995. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV. Oncogene 10: 2397-2401.
57. 57. PENG, S.L., M.E. ROBERT, A.C. HAYDAY & J. CRAFT. 1996. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J. Exp. Med. 184: 1149-1154.
58. 58. DAVIDSON, W.F., T. GIESE & T.N. FREDRICKSON. 1998. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187: 1825-1838.
59. 59. VAN DEN BROEK, M.E., D. KAGI, F. OSSENDORP, R. TOES, S. VAMVAKAS, W.K. LUTZ, C.J. MELIEF, R.M. ZINKERNAGEL & H. HENGARTNER. 1996. Decreased tumor surveillance in perforin-deficient mice. J. Exp. Med. 184: 1781-1790.
60. 60. IRMLER, M., S. HERTIG, H.R. MACDONALD, R. SADOUL, J.D. BECHERER, A. PROUDFOOT, R. SOLARI & J. TSCHOPP. 1995. Granzyme A is an interleukin 1 beta-converting enzyme. J. Exp. Med. 181: 1917-1922.
61. 61. QUAN, L.T., A. CAPUTO, R.C. BLEACKLEY, D.J. PICKUP & G.S. SALVESEN. 1995. Granzyme B is inhibited by the cowpox virus serpin cytokine response modifier A. J. Biol. Chem. 270: 10377-10379.
62. 62. KONDO, S., B.P. BARNA, T. MORIMURA, J. TAKEUCHI, J. YUAN, A. AKBASAK & G.H. BARNETT. 1995. Interleukin-1β-converting enzyme mediates cisplatin-induced apoptosis in malignant glioma cells. Cancer Res. 55: 6166-6171.
63. 63. SCHROTER, M., B. LOWIN, C. BORNER & J. TSCHOPP. 1995. Regulation of Fas(Apo-1/CD95)-and perforin-mediated lytic pathways of primary cytotoxic T lymphocytes by the protooncogene Bcl-2. Eur. J. Immunol 25: 3509-3513.
64. 64. MINN, A.J., C.M. RUDIN, L.H. BOISE & C.B. THOMPSON. 1995. Expression of Bcl-xL can confer a multidrug resistance phenotype. Blood 86: 1903-1910.
65. 65. SCHOTT, A.F., I.J. APEL, G. NUÑEZ & M.F. CLARKE. 1995. Bcl-XL protects cancer cells from p53-mediated apoptosis. Oncogene 11: 1389-1394.
66. 66. FRIESEN, C., I. HERR, P.H. KRAMMER & K.M. DEBATIN. 1996. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nature Med. 2: 574-577.
67. 67. MCGAHON, A.J., A.P. COSTA PEREIRA, L. DALY & T.G. COTTER. 1998. Chemotherapeutic drug-induced apoptosis in human leukemic cells is independent of the Fas (APO-1/CD95) receptor/ligand system. Br. J. Haematol. 101: 539-547.
68. 68. GRIFFITH, T.S., T. BRUNNER, S.M. FLETCHER, D.R. GREEN & T.A. FERGUSON. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270: 1189-1192.
69. 69. BELLGRAU, D., D. GOLD, H. SELAWRY, J. MOORE, A. FRANZUSOFF & R. C. DUKE. 1995. A role for CD95 ligand in preventing graft rejection. Nature 377: 630-632.
70. 70. O'CONNELL, J., M.W. BENNETT, G.C. O'SULLIVAN, J.K. COLLINS & F. SHANAHAN. 1999. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 20: 46-52.
71. 71. BENNETT, M.W., J. O'CONNELL, G.C. O'SULLIVAN, D. ROCHE, C. BRADY, J. KELLY, J.K. COLLINS & F. SHANAHAN. 1999. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut 44: 156-162.
72. 72. BENNETT, M.W., J. O'CONNELL, G.C. O'SULLIVAN, C. BRADY, D. ROCHE, J.K. COLLINS & F. SHANAHAN. 1998. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160: 5669-5675.
73. 73. CARDI, G., J.A. HEANEY, A.R. SCHNED & M.S. ERNSTOFF. 1998. Expression of Fas (APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res. 58: 2078-2080.
74. 74. DANIEL, P.T., A. KROIDL, S. CAYEUX, R. BARGOU, T. BLANKENSTEIN & B. DORKEN. 1997. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J. Immunol. 159: 3808-3815.
75. 75. KHAR, A., C. VARALAKSHMI, B.V.V. PARDHASARADHI, A. MUBARAK ALI & A.L. KUMARI. 1998. Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing Fas ligand: a mechanism of immune evasion. Cell Immunol. 189: 85-91.
76. 76. HAHNE, M., D. RIMOLDI, M. SCHROTER, P. ROMERO, M. SCHREIER, L.E. FRENCH, P. SCHNEIDER, T. BORNAND, A. FONTANA, D. LIENARD, J.-C. CEROTTINI & J. TSCHOPP. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274: 1363-1366.
77. 77. ARAI, H., S.Y. CHAN, D.K. BISHOP & G.J. NABEL. 1997. Inhibition of the alloantibody response by CD95 ligand. Nature Med. 3: 843-848.
78. 78. ARAI, H., D. GORDON, E.G. NABEL & G.J. NABEL. 1997. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. USA 94: 13862-13867.
79. 79. CHEN, J.-J., Y. SUN & G.J. NABEL. 1998. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282: 1714-1717.
80. 80. SEINO, K., K. IWABUCHI, N. KAYAGAKI, R. MIYATA, I. NAGAOKA, A. MATSUZAWA, K. FUKAO, H. YAGITA & K. OKUMURA. 1998. Chemotactic activity of soluble Fas ligand against phagocytes. J. Immunol. 161: 4484-4488.
81. 81. MIWA, K., M. ASANO, R. HORAI, Y. IWAKURA, S. NAGATA & T. SUDA. 1998. Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand. Nature Med. 4: 1287-1292.
82. 82. GRIFFITH, T.S., X. YU, J.M. HERNDON, D.R. GREEN & T.A. FERGUSON. 1996. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5: 7-16.
83. 83. MANN, B., A. GRATCHEV, C. BOHM, M.L. HANSKI, H.D. FOSS, G. DEMEL, B. TROJANEK, I. SCHMIDT-WOLF, H. STEIN, E.O. RIECKEN, H.J. BUHR & C. HANSKI. 1999. FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br. J. Cancer 79: 1262-1269.
84. 84. YOONG, K.F., S.C. AFFORD, S. RANDHAWA, S.G. HUBSCHER & D.H. ADAMS. 1999. Fas/Fas ligand interaction in human colorectal hepatic metastases: a mechanism of hepatocyte destruction to facilitate local tumor invasion. Am. J. Pathol. 154: 693-703.
85. 85. O'CONNELL, J., M.W. BENNETT, G.C. O'SULLIVAN, J.K. COLLINS & F. SHANAHAN. 1999. Fas counter-attack - the best form of tumor defense? Nature Med. 5: 267-268.